Heart failure (HF) is a major public health concern affecting as many as 23 million people worldwide and 10 million in India. The hospitalisation rate and costs of care are enormous. The treatment goals aim to improve their clinical status, functional capacity and quality of life, prevent hospital admission and reduce mortality. There has been substantial progress in the management of HF with pharmacological agents.
Because of high morbidity and mortality, there is an overwhelming need for new therapies that are safe in improving outcomes in HF patients. Neurohormonal antagonists have been shown to improve survival in patients with heart failure with reduced ejection fraction (HFrEF) and are recommended for the treatment of every patient with HFrEF, unless contraindicated or not tolerated. A new compound (LCZ696) that combines the moieties of an angiotensin receptor blocker (ARB;…
